BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27185284)

  • 1. Outcomes of intensity-modulated radiotherapy as primary treatment for oropharyngeal squamous cell carcinoma - a European singleinstitution analysis.
    Bird T; De Felice F; Michaelidou A; Thavaraj S; Jeannon JP; Lyons A; Oakley R; Simo R; Lei M; Guerrero Urbano T
    Clin Otolaryngol; 2017 Feb; 42(1):115-122. PubMed ID: 27185284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design.
    Ward MC; Ross RB; Koyfman SA; Lorenz R; Lamarre ED; Scharpf J; Burkey BB; Joshi NP; Woody NM; Prendes B; Houston N; Reddy CA; Greskovich JF; Adelstein DJ
    JAMA Otolaryngol Head Neck Surg; 2016 Dec; 142(12):1164-1170. PubMed ID: 27438230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective functional outcomes in sequential population based cohorts of stage III/ IV oropharyngeal carcinoma patients treated with 3D conformal vs. intensity modulated radiotherapy.
    Kerr P; Myers CL; Butler J; Alessa M; Lambert P; Cooke AL
    J Otolaryngol Head Neck Surg; 2015 May; 44(1):17. PubMed ID: 25964113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
    Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
    Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.
    Naik M; Ward MC; Bledsoe TJ; Kumar AM; Rybicki LA; Saxton JP; Burkey BB; Greskovich JF; Adelstein DJ; Koyfman SA
    Oral Oncol; 2015 Aug; 51(8):800-4. PubMed ID: 25977228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and outcome of intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy for oropharyngeal cancer: a matched-pair analysis.
    Al-Mamgani A; Van Rooij P; Tans L; Teguh DN; Levendag PC
    Technol Cancer Res Treat; 2013 Apr; 12(2):123-30. PubMed ID: 23098281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of outcomes using intensity-modulated radiation therapy and 3-dimensional conformal radiation therapy in treatment of oropharyngeal cancer.
    Lohia S; Rajapurkar M; Nguyen SA; Sharma AK; Gillespie MB; Day TA
    JAMA Otolaryngol Head Neck Surg; 2014 Apr; 140(4):331-7. PubMed ID: 24557509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Outcomes for T4 Oropharyngeal Squamous Cell Carcinoma.
    Zenga J; Wilson M; Adkins DR; Gay HA; Haughey BH; Kallogjeri D; Michel LS; Paniello RC; Rich JT; Thorstad WL; Nussenbaum B
    JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1118-27. PubMed ID: 25902372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of neck dissection in N2-3 oropharyngeal squamous cell carcinomas treated with definitive chemoradiotherapy: An observational real-life study].
    Klausner G; Troussier I; Kreps S; Fabiano E; Laccourreye O; Giraud P
    Cancer Radiother; 2021 Dec; 25(8):771-778. PubMed ID: 34175226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMRT-SIB with concurrent and neo-adjuvant platinum-based chemotherapy for locally advanced head and neck squamous cell cancer: analysis of clinical outcomes in a retrospective series of a single institution.
    Mazzeo E; Antognoni P; Parmiggiani M; D'Ambrosio C; De Marco G; Marra L; Gottardi G; Bertoni F
    Tumori; 2014; 100(6):652-9. PubMed ID: 25688499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era.
    Sher DJ; Nedzi L; Khan S; Hughes R; Sumer BD; Myers LL; Truelson JM; Koshy M
    JAMA Otolaryngol Head Neck Surg; 2016 Aug; 142(8):777-88. PubMed ID: 27368076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of intensity-modulated radiotherapy in Stage IV head-and-neck squamous cell carcinoma.
    Dirix P; Nuyts S
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1373-80. PubMed ID: 20362402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy.
    Roskies M; Kay-Rivest E; Mascarella MA; Sultanem K; Mlynarek A; Hier M
    J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):50. PubMed ID: 27724969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
    Zumsteg ZS; Lok BH; Ho AS; Drill E; Zhang Z; Riaz N; Shiao SL; Ma J; McBride SM; Tsai CJ; Baxi SS; Sherman EJ; Lee NY
    Cancer; 2017 Apr; 123(8):1345-1353. PubMed ID: 27984656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Adjuvant Chemotherapy in Surgically Managed, p16-Positive Oropharyngeal Squamous Cell Carcinoma.
    Skillington SA; Kallogjeri D; Lewis JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2017 Mar; 143(3):253-259. PubMed ID: 27918781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.
    Setton J; Caria N; Romanyshyn J; Koutcher L; Wolden SL; Zelefsky MJ; Rowan N; Sherman EJ; Fury MG; Pfister DG; Wong RJ; Shah JP; Kraus DH; Shi W; Zhang Z; Schupak KD; Gelblum DY; Rao SD; Lee NY
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):291-8. PubMed ID: 21167652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnitude of benefit for adjuvant radiotherapy following minimally invasive surgery in intermediate to high risk HPV-positive oropharyngeal squamous cell carcinoma.
    Pasalic D; Funk RK; García JJ; Price DL; Price KA; Harmsen WS; Patel SH; Young GD; Foote RL; Moore EJ; Ma DJ
    Oral Oncol; 2018 Jul; 82():181-186. PubMed ID: 29909895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.